Study of Adaptive Radiotherapy for High-Grade Glioma Based on Interfraction MRI
Abstract
Background: Currently, there is no clear guidance on the appropriate population or timing for adaptive radiotherapy (ART) in high-grade glioma (HGG) patients. This study aims to provide individualized ART for HGG patients.
Methods: Participants received standard "radiotherapy combined with temozolomide" and underwent MRI before radiotherapy (FX0), after fraction 10 (FX10), and after fraction 20 (FX20). The primary endpoint was anatomical and dosimetric changes in targets and organs at risk (OARs).
Results: Among the 73 eligible patients, significant anatomical changes occurred during chemoradiotherapy, particularly at FX10. ART significantly improved target dose coverage and reduced OAR doses compared with projection plans. Univariable and multivariable logistic regression analysis identified Relative volume change (Vrel)_CTV ≥ 7% as an independent risk factor for dosimetric changes, with IDH wild-type and tumor diameters < 5 cm as independent risk factors. Median follow-up was 12 months; median progression-free survival (PFS) was 18 months. D_migration_max_CTV ≥ 8.5 mm was associated with worse PFS.
Conclusions: Implementing ART after FX10 is recommended. HGG patients with wild-type IDH and tumor diameters < 5 cm should be prioritized for ART. Patients with D_migration_max_CTV ≥ 8.5 mm require more intensive treatment.
Trial registration: The trial was prospectively registered (ClinicalTrials.gov, NCT06201351).
How strong is the evidence?
Evidence Hub reads this as a clinical trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 73 participants or records.
Read the paper
Related studies
- Preliminary Toxicity Analysis of 3DCRT versus IMRT on the High Dose Arm of the RTOG 0126 Prostate Cancer Trial
- Adaptive Radiotherapy for Head and Neck Cancer: Initial Clinical Outcomes from a Prospective Trial
- American Association of Physicists in Medicine Task Group 263: Standardizing Nomenclatures in Radiation Oncology
- Motion Management Strategies and Technical Issues Associated with Stereotactic Body Radiotherapy of Thoracic and Upper Abdominal Tumors: A Review from NRG Oncology
- High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: treatment description and preliminary results of a phase I/II clinical trial
- Highly efficient training, refinement, and validation of a knowledge-based plan quality control system for radiotherapy clinical trials
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.